Dupilumab biosimilar (Jingxing Pharmaceutical)

N/A

Report date: 2026/03/12 20:00:16

Base Information

Drug NameDupilumab biosimilar (Jingxing Pharmaceutical)
Drug Alias NameDupilumab biosimilar (Jingxing Pharmaceutical)GS101GS-101GS-101 (Jingxing Pharmaceutical)
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-4 receptor subunit alpha inhibitorsInterleukin-4 inhibitorsInterleukin-13 inhibitors
TargetsInterleukin-13Interleukin-4 receptor subunit alphaInterleukin-4
Therapy Area/IndicationsDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJiangsu Jingxing Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Genscend Biopharmaceutical Co LtdJiangsu Jingxing Pharmaceutical Technology Co LtdJiangsu Saifushi Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A